FindTrial
Sign In

to assess the efficacy of acitretin in acquired dermatoses with dermal hyperpigmentation

Efficacy of acitretin in acquired dermal macular hyperpigmentation: An open label pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/06/014588
Enrollment
25
Registered
2018-06-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- acquired dermal macular hyperpigmentation/ Lichen planus pigmentosus

Interventions

Intervention1: Acitretin: 25 mg capsule of acitretin shall be prescribed once daily after liver function tests and lipid profile is normal. The route shall be per oral. These investigations shall be r

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with a cliniopathological diagnosis of ADMH (acquired dermal macular hyperpigmentation) 2. Age >18 years

Exclusion criteria

Exclusion criteria: 1. Age 2. Pregnancy/Lactation 3. Child bearing age females with incomplete family status 4. Patients refusing practice of contraceptive measures 5. Patients with severe hepatic, renal disease or dyslipidemia 6. Pre existing malignancy

Design outcomes

Primary

MeasureTime frame
To assess the efficacy of acitretin in reducing the severity of acquired dermal macular hyperpigmentationTimepoint: 24 weeks treatment, 12 weeks follow-up.—

Secondary

MeasureTime frame
1. To assess the efficacy of acitretin in reducing the activity of acquired dermal macular hyperpigmentation 2. To assess the safety of acitretin in acquired dermal macular hyperpigmentation Timepoint: 24 weeks treatment, 12 weeks follow-up.—

Countries

India

Contacts

Public ContactKeshavamurthy Vinay

PGIMER

vinay.keshavmurthy@gmail.com8872993222

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026